Contemporary Issues in Lung CancerJones & Bartlett Publishers, 2009 M02 12 - 364 pages In the United States, lung cancer is the second most commonly diagnosed cancer and the leading cause of cancer death. Even more devastating is its five-year survival rate of only 15.8%. Despite these dismal facts, lung cancer receives little national attention and research and funding for lung cancer lags behind other cancers. The intent of Contemporary Issues in Lung Cancer: A Nursing Perspective Second Edition is to provide oncology nurses and healthcare professionals with in-depth information on the issues that surround this disease, so that they might impact both education and research and provide better care for their patients. |
From inside the book
Results 1-5 of 94
Page v
... Chemotherapy and Lung Cancer 65 Pamela Hallquist Viale 6 New Advances in Radiotherapy for Lung Cancer 107 Giselle J. Moore-Higgs Kenneth R. Olivier Part Three Special Issues Facing Individuals with Lung Cancer . . .117 7 Surviving ...
... Chemotherapy and Lung Cancer 65 Pamela Hallquist Viale 6 New Advances in Radiotherapy for Lung Cancer 107 Giselle J. Moore-Higgs Kenneth R. Olivier Part Three Special Issues Facing Individuals with Lung Cancer . . .117 7 Surviving ...
Page ix
... chemotherapy plays in treating this disease are discussed in depth. The chapters in Part Three address the special issues that face lung cancer patients: fatigue, end of life, nutrition, dyspnea, and radon exposure. In Part Four, the ...
... chemotherapy plays in treating this disease are discussed in depth. The chapters in Part Three address the special issues that face lung cancer patients: fatigue, end of life, nutrition, dyspnea, and radon exposure. In Part Four, the ...
Page 20
... chemotherapy, thus suggesting that amplification of MYC is a poor prognostic factor (Onn, et al., 2006). Table 2–1 Major Genetic Aberrations in NSCLC and SCLC NSCLC. Source: Scagliotti, N., & Hirsch, F. (2004). The biology of epidermal ...
... chemotherapy, thus suggesting that amplification of MYC is a poor prognostic factor (Onn, et al., 2006). Table 2–1 Major Genetic Aberrations in NSCLC and SCLC NSCLC. Source: Scagliotti, N., & Hirsch, F. (2004). The biology of epidermal ...
Page 25
... chemotherapy upon the cancer (Potti, et al., 2006). With this knowledge, researchers are hoping to identify the best drug to treat an individual's cancer (Hsu, et al., 2008). Limitless. Replicative. Potential: Telomerase. While the ...
... chemotherapy upon the cancer (Potti, et al., 2006). With this knowledge, researchers are hoping to identify the best drug to treat an individual's cancer (Hsu, et al., 2008). Limitless. Replicative. Potential: Telomerase. While the ...
Page 26
... chemotherapy are ongoing (Liao, Wang, Zhenqiong, Feng, & Zhu, 2001; Sekido, et al., 2005; Onn, et al., 2006). Tissue. Invasion. and. Metastases. Another area of exploration in the development and progression of lung cancer is cell adhesion ...
... chemotherapy are ongoing (Liao, Wang, Zhenqiong, Feng, & Zhu, 2001; Sekido, et al., 2005; Onn, et al., 2006). Tissue. Invasion. and. Metastases. Another area of exploration in the development and progression of lung cancer is cell adhesion ...
Contents
Oncology Treatment Modalities | 45 |
Special Issues Facing Individuals with Lung Cancer | 117 |
Psychosocial Issues of Individuals with Lung Cancer | 231 |
Assistance and Resources for Individuals Facing Lung Cancer | 255 |
Media and Future Research Directions | 301 |
Index | 353 |
Other editions - View all
Common terms and phrases
adjuvant agents aprepitant associated bevacizumab breathing breathlessness Bruera carboplatin carcinoma cell lung cancer chemotherapy chronic cisplatin Clinical Oncology clinical trials combination diagnosis disease docetaxel dose drug dyspnea EGFR erlotinib etoposide evaluation evidence-based factors fatigue gefitinib gemcitabine gene improve increased individuals indoor radon Internet intervention irinotecan Journal of Clinical lung cancer patients Medicine ment metastatic months NCCN nicotine non-small cell lung NSCLC Nursing Forum Oncology Nursing Oncology Nursing Forum paclitaxel palliative palliative care patient navigation patients and families patients with lung pemetrexed phase potential pulmonary quit smoking radiation therapy radiotherapy radon randomized receptors regimen reported resection respiratory response rate risk role SCLC score screening Sekido side effects small cell lung smoking cessation stage strategies support group surgical survival rate Symptom Management Table tients tion tobacco topotecan toxicity treat treatment tumor versus vinorelbine weight loss